A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Daniel R Greenwald; Hailun Li; Selina M Luger; Ronald S Go; David King; Taral Patel; Randy D Gascoyne; Jill Kolesar; Brad S Kahl; Sandra Horning

doi:10.1186/1756-8722-6-46

Back

A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Journal article

Open access

Peer reviewed

A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Daniel R Greenwald, Hailun Li, Selina M Luger, Ronald S Go, David King, Taral Patel, Randy D Gascoyne, Jill Kolesar, Brad S Kahl and Sandra Horning

Journal of hematology and oncology, Vol.6(1), pp.46-46

07/05/2013

DOI: 10.1186/1756-8722-6-46

PMCID: PMC3716977

PMID: 23829878

Files and links (1)

url

https://doi.org/10.1186/1756-8722-6-46View

Published (Version of record) Open Access

Abstract

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

Adult

Aged

Aged, 80 and over

Antineoplastic Agents - adverse effects

Antineoplastic Agents - therapeutic use

Female

Humans

Lymphoma, Large B-Cell, Diffuse - drug therapy

Male

Middle Aged

Neoplasm Recurrence, Local - drug therapy

Niacinamide - adverse effects

Niacinamide - analogs & derivatives

Niacinamide - therapeutic use

Phenylurea Compounds - adverse effects

Phenylurea Compounds - therapeutic use

Prognosis

Treatment Outcome

Details

Title: Subtitle: A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
Creators: Daniel R Greenwald - Stanford University
Hailun Li - Dana-Farber Cancer Institute
Selina M Luger - University of Pennsylvania
Ronald S Go - Gundersen Health System
David King - Mercy Medical Center
Taral Patel - Columbus Community Clinical Oncology Program
Randy D Gascoyne - BC Cancer Agency
Jill Kolesar - University of Wisconsin–Madison
Brad S Kahl - University of Wisconsin–Madison
Sandra Horning - Stanford University
Resource Type: Journal article
Publication Details: Journal of hematology and oncology, Vol.6(1), pp.46-46
DOI: 10.1186/1756-8722-6-46
PMID: 23829878
PMCID: PMC3716977
ISSN: 1756-8722
eISSN: 1756-8722
Grant note: U10 CA021115 / NCI NIH HHS CA21076 / NCI NIH HHS P30 CA014520 / NCI NIH HHS CA-23318 / NCI NIH HHS CA66636 / NCI NIH HHS CA15488 / NCI NIH HHS CA21115 / NCI NIH HHS U24 CA114737 / NCI NIH HHS CA23318 / NCI NIH HHS
Language: English
Date published: 07/05/2013
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
Record Identifier: 9984695786602771

Metrics

14 Record Views

12 Times Cited - Web of Science